Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine

References

• Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43, S5–S 12 (2004).
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343–349 (1991).
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327, 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, S40–S47 (2004).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Ioos V et al. Who benefits from long-term calcium channel-blocker therapy in primary pulmonary arterial hypertension? Am. J. Respir. Crit. Care Med. 167 (2003) (Abstract 440).
   PubMedGoogle Scholar
• Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70, 580–587 (1984).
   PubMed Web of Science ®Google Scholar
• Frank H, Mlczoch J, Huber K et al. The effect of anticoagulant therapy in primary and anorectic-induced pulmonary hypertension. Chest 112, 714–721 (1997).
   PubMed Web of Science ®Google Scholar
• Jeffrey TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis.45, 173–202 (2002).
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327, 70–75 (1992).
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333, 214–221 (1995).
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732–1739 (1993).
   PubMed Web of Science ®Google Scholar
• Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114(Suppl. 3), S208–S212 (1998).
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159, 1925–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112, 485–491 (1990).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425–434 (2000).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, McGoon MD et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121, 409–415 (1994).
   PubMed Web of Science ®Google Scholar
• Shapiro SM, Oudiz RJ, Cao T et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J. Am. Coll. Cardiol. 30, 343–349 (1997).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106, 1477–1482 (2002).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40, 780–788 (2002).
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 167, 580–586 (2003).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338, 273–277 (1998).
   PubMed Web of Science ®Google Scholar
• Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J. Am. Coll. Cardiol. 34, 1184–1187 (1999).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Genthner DE, Panella MM et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann. Intern. Med. 130, 740–743 (1999).
   PubMed Web of Science ®Google Scholar
• Robbins IM, Gaine SP, Schilz R et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 117, 14–18 (2000).
   PubMed Web of Science ®Google Scholar
• Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 118, 1229–1230 (2000).
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Frantz RP, McGoon MD et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate-to-severe portopulmonary hypertension. Hepatology 30, 641–648 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99, 1858–1865 (1999).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165, 800–804 (2002).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496–1502 (2002).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41, 2119–2125 (2003).
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358, 1119–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169, 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Galie N, Badesch D et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(7) (2004) (Abstract 210).
   PubMedGoogle Scholar
• Ghofrani HA. Sildenafil use in pulmonary arterial hypertension (SUPER-1 trial). Presented at the 70th Annual Meeting of the American College of Chest Physicians. Seattle, WA, USA 23–28 October 2004.
   Google Scholar
• Galie N, Rubin LJ. Pulmonary arterial hypertension. Epidemiology, pathobiology, assessment, and therapy. J. Am. Coll. Cardiol. 43(12 Suppl S), S89–S90 (2004).
   Google Scholar
• Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl.) (2004).
   Google Scholar
• Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24, 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Channick RN, Kim N, Lombardi S et al. Addition of bosentan to patients with pulmonary arterial hypertension receiving chronic epoprostenol or treprostinil is well tolerated and allows for weaning or discontinuation of prostacyclin in some patients. Am. J. Respir. Crit. Care Med. 167(7), A441 (2003).
   Google Scholar
• Rayburn BK, Benza RL, Tallaj JA et al. The use of bosentan and a prostacyclin analog in the treatment of primary pulmonary hypertension. International Society for Heart and Lung Transplantation Meeting. Vienna, Austria, 8–12 April 2003 (Abstract 241).
   Google Scholar
• Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 126, 808–815 (2004).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136(7), 515–522 (2002).
   PubMed Web of Science ®Google Scholar
• Stiebellehner L, Petkov V, Vonbank K et al. Long-term treatment with oral sildenafil in addition to continuous iv. epoprostenol in patients with pulmonary arterial hypertension. Chest 123, 1293–1295 (2003).
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Gulati M, Rich S. Combination therapy of subcutaneous treprostinil and oral sildenafil: a proof of concept of pilot trial. Am. J. Respir. Crit. Care Med. 169(Suppl. 7), A211 (2004).
   Google Scholar
• Vachiery JL, Hill N, Zwicke D et al. Transitioning from iv. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121, 1561–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Kim NK, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 124, 1612–1615 (2003).
   PubMed Web of Science ®Google Scholar
• Tapson V, Barst R, Horn E et al. Safety and efficacy of chronic intravenous treprostinil in patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(Suppl. 7), A172 (2004).
   Google Scholar
• Voswinckel R, Enke B, Kreckel A et al. Inhaled treprostinil sodium for the treatment of pulmonary hypertension. Circulation 110(Suppl. 17), 1414 (2004).
   Google Scholar
• Arai H, Hori S, Aramori I et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730–732 (1990).
   PubMed Web of Science ®Google Scholar
• Seo B, Oemar BS, Siebenmann R et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89, 1203–1208 (1994).
   PubMed Web of Science ®Google Scholar
• Davie N, Haleen SJ, Upton PD et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165, 398–405 (2002).
   PubMed Web of Science ®Google Scholar
• de Nucci G, Thomas R, D’Orleans-Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl Acad. Sci. USA 85, 9797–9800 (1988).
   PubMed Web of Science ®Google Scholar
• MacLean MR, Docherty CC, McCulloch KM et al. Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries. Pulm. Pharmacol. Ther. 11, 147–149 (1998).
   PubMed Web of Science ®Google Scholar
• Jasmin JF, Lucas M, Cernacek P et al. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103, 314–318 (2001).
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 487–492 (2000).
   PubMed Web of Science ®Google Scholar
• Paciocco G, Martinez FJ, Bossone E et al. Oxygen desaturation on the 6-minute walk test and mortality in untreated primary pulmonary hypertension. Eur. Respir. J. 17, 647–652 (2001).
   PubMed Web of Science ®Google Scholar
• Sun XG, Hansen JE, Oudiz RJ et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 104, 429–435 (2001).
   PubMed Web of Science ®Google Scholar
• Wax D, Garifano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 116, 914–920 (1999).
   PubMed Web of Science ®Google Scholar
• Wensel R, Opitz C, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106, 319–324 (2002).
   PubMed Web of Science ®Google Scholar
• Oudiz R, Barst R, Hansen JE et al. Cause of correlation failure between cardiopulmonary exercise testing and 6-minute walk distance in patients with pulmonary arterial hypertension. Circulation 110(17 Suppl.), 2496 (2004).
   Google Scholar
• Hansen JE, Sun X, Yasunobu Y et al. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest 126, 816–824 (2004).
   PubMed Web of Science ®Google Scholar
• Hinderliter AL, Willis PW IV, Barst RJ et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right-ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 95, 1479–1486 (1997).
   PubMed Web of Science ®Google Scholar
• Galie N, Hinderliter AL, Torbicki A et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41, 1380–1386 (2003).
   PubMed Web of Science ®Google Scholar
• Bellenger NG, Grothues F, Smith GC, Pennell DJ. Quantification of right and left-ventricular function by cardiovascular magnetic resonance. Herz 25, 392–399 (2000).
   PubMed Web of Science ®Google Scholar
• Marcus JT, Vonk-Noordegraaf A, Roeleveld RJ et al. Impaired left-ventricular filling due to right-ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest 119, 1761–1765 (2001).
   PubMed Web of Science ®Google Scholar
• Sulica R, Rosenbluth A, Goldman J et al. A novel noninvasive marker of pulmonary hypertension using magnetic resonance imaging. Am. J. Respir. Crit. Care Med. 165(Suppl. 8), A336 (2002).
   Google Scholar
• Sulica R, Sanz J, Fearon-Clarke J et al. Intravenous nesiritide improves hemodynamics in a randomized, double-blind, placebo-controlled trial in patients with pulmonary hypertension and right-ventricular failure. Right atrial dimension by cardiac MRI is a reliable, novel treatment end point in pulmonary hypertension. Circulation 110(Suppl. 17), 2414 (2004).
   Google Scholar
• Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102, 865–870 (2000).
   PubMed Web of Science ®Google Scholar
• Kakishita M, Nishikimi T, Okano Y et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin. Sci. (Lond) 96, 33–39 (1999).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Satoh T et al. Serum uric acid levels correlate with severity and mortality of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 160, 487–492 (1999).
   PubMed Web of Science ®Google Scholar
• Torbicki A, Kurzyna M, Kuca P et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108, 844–848 (2003).
   PubMed Web of Science ®Google Scholar
• Davie NJ, Crossno JT Jr, Frid MG et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L668–L678 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nakamura T, Toba T et al. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng. 10, 771–779 (2004).
   PubMedGoogle Scholar
• Yeager ME, Halley GR, Golpon HA et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 88, E2–E11 (2001).
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Kasahara Y, Alger L et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427–438 (2001).
   PubMed Web of Science ®Google Scholar
• Campbell AI, Zhao Y, Sandhu R et al. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104, 2242–2248 (2001).
   PubMed Web of Science ®Google Scholar
• Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67, 737–744 (2000).
   PubMed Web of Science ®Google Scholar
• Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor of the TGF-β family. J. Med. Genet 37, 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Humbert M, Deng Z, Simonneau G et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur. Respir. J. 20, 518–523 (2002).
   PubMed Web of Science ®Google Scholar
• Roberts KE, McElroy JJ, Wong WPK et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J. 24, 371–374 (2004).
   PubMed Web of Science ®Google Scholar
• Du L, Sullivan CC, Chu D et al. Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348, 500–509 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao YD, Campbell AI, Robb M et al. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ. Res. 92, 984–991 (2003).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Chaouat A, Morrell N et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108, 1839–1844 (2003).
   PubMed Web of Science ®Google Scholar
• Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ. Res. 94, 1263–1270 (2004).
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111, 1339–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M et al. Hemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 84, 653–658 (2000).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kyotani S, Uematsu M et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 109, 351–356 (2004).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Okumura H, Uematsu M et al. Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am. J. Physiol. Heart Circ. Physiol. 285, H2125–H2131 (2003).
   PubMed Web of Science ®Google Scholar
• Herve P, Launay JM, Scrobohaci LM et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249–254 (1995).
   PubMed Web of Science ®Google Scholar
• Morecroft I, Heeley RP, Prentice HM et al. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br. J. Pharmacol. 128, 730–734 (1999).
   PubMed Web of Science ®Google Scholar
• Welsh DJ, Harnett M, MacLean M et al. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine-2A receptor and transporter. Am. J. Respir. Crit. Care Med. 170, 252–259 (2004).
   PubMed Web of Science ®Google Scholar
• Keegan A, Morecroft I, Smillie D et al. Contribution of the 5-HT (1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT (1B)-receptor knockout mice and the 5-HT (1B/1D)-receptor antagonist GR 127935. Circ. Res. 89, 1231–1239 (2001).
   PubMed Web of Science ®Google Scholar
• Hironaka E, Hongo M, Sakai A et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 60, 692–699 (2003).
   PubMed Web of Science ®Google Scholar
• Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 168, 487–493 (2003).
   PubMed Web of Science ®Google Scholar
• Yuan JX, Wang J, Juhaszova M et al. Attenuated K-channel gene transcription in primary pulmonary hypertension. Lancet 351, 726–727 (1998).
   PubMed Web of Science ®Google Scholar
• Geraci MW, Moore M, Gessell T et al. Gene expression pattern in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ. Res. 88, 555–562 (2001).
   PubMed Web of Science ®Google Scholar
• Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105(1), 21–34 (2000).
   PubMed Web of Science ®Google Scholar
• Cowan KN, Heilbut A, Humpl T et al. Complete reversal of fatal pulmonary hypertension in rats by serine elastase inhibitor. Nature Med. 6, 698–702 (2000).
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 166, 1403–1408 (2002).
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108, 1640–1645 (2003).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Oya H et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 163, 887–891 (2001).
   PubMed Web of Science ®Google Scholar
• Surdacki A, Zmudka K, Bieron K et al. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. Wien Klin Wochenschr. 106, 521–526 (1994).
   PubMed Web of Science ®Google Scholar
• Boger RH, Mugge A, Bode-Boger SM et al. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int. J. Clin. Pharmacol. Ther. 34, 323–328 (1996).
   PubMed Web of Science ®Google Scholar
• Langleben D, Christman BW, Barst RJ et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am. Heart J. 143, E4 (2002).
   PubMed Web of Science ®Google Scholar